



The Role of NK Cells in Cancer Immunotherapy: Mechanisms, Evasion Strategies, and Therapeutic Advances

Guest Editor:

**Dr. Maria Eugenia Garcia
Rubino**

Nanoscopy-UGR Laboratory,
Department of Physical
Chemistry, Faculty of Pharmacy,
Unidad de Excelencia en Química
Aplicada a Biomedicina y
Medioambiente (UEQ), University
of Granada, C. U. Cartuja, 18071
Granada, Spain

Deadline for manuscript
submissions:

closed (31 May 2026)

Message from the Guest Editor

Dear Colleagues,

Natural killer (NK) cells play a pivotal role in immune surveillance and the elimination of tumor cells. Through a set of activating and inhibitory receptors, NK cells recognize and destroy malignant cells; however, tumors have developed evasion mechanisms with which to escape NK-cell-mediated destruction, posing a significant challenge in the field of immunotherapy. This Special Issue explores the mechanisms of NK cell action in the cancer context, the strategies tumors employ to evade NK cell activity, and emerging NK-cell-based therapies, such as CAR-NK cells and combination therapies. Finally, recent clinical trials and future challenges in the clinical implementation of these therapies will be discussed.

Dr. Maria Eugenia Garcia Rubino
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)